Christina Ackermann - Bausch Lomb Gen VP
| BLCO Stock | USD 15.32 0.16 1.03% |
Insider
Christina Ackermann is Gen VP of Bausch Lomb Corp
| Age | 59 |
| Address | 520 Applewood Crescent, Vaughan, ON, Canada, L4K 4B4 |
| Phone | (905) 695-7700 |
| Web | https://www.bausch.com |
Bausch Lomb Management Efficiency
The company has return on total asset (ROA) of 0.0108 % which means that it generated a profit of $0.0108 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0469) %, meaning that it created substantial loss on money invested by shareholders. Bausch Lomb's management efficiency ratios could be used to measure how well Bausch Lomb manages its routine affairs as well as how well it operates its assets and liabilities. As of the 7th of June 2024, Return On Tangible Assets is likely to grow to -0.05. In addition to that, Return On Capital Employed is likely to drop to 0.01. At this time, Bausch Lomb's Intangibles To Total Assets are very stable compared to the past year. As of the 7th of June 2024, Debt To Assets is likely to grow to 0.36, while Total Assets are likely to drop about 12.8 B.Similar Executives
| Showing other executives | INSIDER Age | ||
| Deborah Yount | AtriCure | 58 | |
| FACC MD | Becton Dickinson and | N/A | |
| Gerard III | The Cooper Companies | 59 | |
| CCEP CCEP | AtriCure | 52 | |
| Vinayak Doraiswamy | AtriCure | 52 | |
| Amy Wakeham | ResMed Inc | N/A | |
| Kevin Thornal | Hologic | 50 | |
| James Winters | Teleflex Incorporated | 48 | |
| Nikolay Samusik | Akoya Biosciences | N/A | |
| Margaret Buckley | Alcon AG | N/A | |
| Brian Bonnell | ICU Medical | 50 | |
| Candace Matthews | AptarGroup | 61 | |
| Angela CPA | AtriCure | 46 | |
| Scott Maw | Alcon AG | 53 | |
| AM AM | ResMed Inc | 80 | |
| Olga Guyette | Haemonetics | N/A | |
| Ching leong | Becton Dickinson and | 53 | |
| Lynn Bleil | Alcon AG | 56 | |
| Ines Poeschel | Alcon AG | 52 | |
| Marilee MBA | Akoya Biosciences | 65 | |
| Franck Leveiller | Alcon AG | N/A | |
Management Performance
| Return On Equity | -0.0469 | ||||
| Return On Asset | 0.0108 |
Bausch Lomb Corp Leadership Team
Elected by the shareholders, the Bausch Lomb's board of directors comprises two types of representatives: Bausch Lomb inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bausch. The board's role is to monitor Bausch Lomb's management team and ensure that shareholders' interests are well served. Bausch Lomb's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bausch Lomb's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Joseph Gordon, Surgical Consumer | ||
| Osama Eldessouky, Executive CFO | ||
| Frederick Munsch, Controller VP | ||
| Asli Gevgilili, Executive Officer | ||
| Christina Ackermann, Gen VP | ||
| Dennis Asharin, Ex Officer | ||
| Yehia MD, Executive officer | ||
| Brenton JD, CEO Chairman | ||
| A Bailey, Executive Officer | ||
| Louis Yu, Ex Officer | ||
| Joseph Papa, CEO Director | ||
| T Crawford, Chief Officer | ||
| Kelly Webber, Ex Officer | ||
| Jonathon Kellerman, Chief Officer | ||
| Manisha Narasimhan, Chief Officer | ||
| MBA CPFA, Executive Officer |
Bausch Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Bausch Lomb a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0469 | ||||
| Return On Asset | 0.0108 | ||||
| Profit Margin | (0.08) % | ||||
| Operating Margin | 0.01 % | ||||
| Current Valuation | 9.78 B | ||||
| Shares Outstanding | 351.48 M | ||||
| Shares Owned By Insiders | 88.57 % | ||||
| Shares Owned By Institutions | 10.86 % | ||||
| Number Of Shares Shorted | 1.88 M | ||||
| Price To Earning | 39.08 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectAdditional Information and Resources on Investing in Bausch Stock
When determining whether Bausch Lomb Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bausch Lomb's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bausch Lomb Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bausch Lomb Corp Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bausch Lomb Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bausch Lomb. If investors know Bausch will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bausch Lomb listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.89) | Earnings Share (0.96) | Revenue Per Share 12.298 | Quarterly Revenue Growth 0.18 | Return On Assets 0.0108 |
The market value of Bausch Lomb Corp is measured differently than its book value, which is the value of Bausch that is recorded on the company's balance sheet. Investors also form their own opinion of Bausch Lomb's value that differs from its market value or its book value, called intrinsic value, which is Bausch Lomb's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bausch Lomb's market value can be influenced by many factors that don't directly affect Bausch Lomb's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bausch Lomb's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bausch Lomb is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bausch Lomb's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.